Amenorrhea after lung cancer treatment

Elizabeth J. Cathcart-Rake, Kathryn J Ruddy, Ruchi Gupta, Walter K Kremers, Kelly Gast, H. Irene Su, Ann H. Partridge, Elizabeth A Stewart, Han Liu, Yanqi He, Ping Yang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

OBJECTIVE: More than 5,000 premenopausal women are diagnosed with lung cancer annually in the United States. Limited data exist regarding the risk of treatment-related amenorrhea, a surrogate for infertility and early menopause, after systemic therapies for lung cancer. METHODS: Premenopausal women diagnosed with lung cancer under age 50 were surveyed at diagnosis and annually thereafter about their menstrual status as a part of the Mayo Clinic Epidemiology and Genetics of Lung Cancer Research Program. Types of lung cancer-directed treatments were recorded, and frequencies of self-reported menopause at each survey were calculated. RESULTS: A cohort of 182 premenopausal women were included in this study, with average age at lung cancer diagnosis 43 years (SD 6). Among the 85 patients who received chemotherapy, 64% self-reported that they had become menopausal within a year of diagnosis. Platinum salts were universally included in these chemotherapy regimens, and the majority of these women also received taxanes within 1 year of diagnosis. Only 15% of the 94 patients who did not receive systemic therapy within 1 year of diagnosis experienced self-reported menopause. Three patients received targeted therapy alone, two of whom remained premenopausal at the final qualifying survey, completed a median of 3 years after diagnosis. CONCLUSIONS: Chemotherapy for lung cancer patients appears to increase risk of early loss of menses in survivors.

Original languageEnglish (US)
Pages (from-to)306-310
Number of pages5
JournalMenopause (New York, N.Y.)
Volume26
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Amenorrhea
Lung Neoplasms
Menopause
Drug Therapy
Therapeutics
Taxoids
Menstruation
Molecular Epidemiology
Platinum
Infertility
Survivors
Salts
Research

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Amenorrhea after lung cancer treatment. / Cathcart-Rake, Elizabeth J.; Ruddy, Kathryn J; Gupta, Ruchi; Kremers, Walter K; Gast, Kelly; Su, H. Irene; Partridge, Ann H.; Stewart, Elizabeth A; Liu, Han; He, Yanqi; Yang, Ping.

In: Menopause (New York, N.Y.), Vol. 26, No. 3, 01.03.2019, p. 306-310.

Research output: Contribution to journalArticle

Cathcart-Rake, EJ, Ruddy, KJ, Gupta, R, Kremers, WK, Gast, K, Su, HI, Partridge, AH, Stewart, EA, Liu, H, He, Y & Yang, P 2019, 'Amenorrhea after lung cancer treatment', Menopause (New York, N.Y.), vol. 26, no. 3, pp. 306-310. https://doi.org/10.1097/GME.0000000000001199
Cathcart-Rake, Elizabeth J. ; Ruddy, Kathryn J ; Gupta, Ruchi ; Kremers, Walter K ; Gast, Kelly ; Su, H. Irene ; Partridge, Ann H. ; Stewart, Elizabeth A ; Liu, Han ; He, Yanqi ; Yang, Ping. / Amenorrhea after lung cancer treatment. In: Menopause (New York, N.Y.). 2019 ; Vol. 26, No. 3. pp. 306-310.
@article{b3d0b9276e0f473b8a5461e10c8ca119,
title = "Amenorrhea after lung cancer treatment",
abstract = "OBJECTIVE: More than 5,000 premenopausal women are diagnosed with lung cancer annually in the United States. Limited data exist regarding the risk of treatment-related amenorrhea, a surrogate for infertility and early menopause, after systemic therapies for lung cancer. METHODS: Premenopausal women diagnosed with lung cancer under age 50 were surveyed at diagnosis and annually thereafter about their menstrual status as a part of the Mayo Clinic Epidemiology and Genetics of Lung Cancer Research Program. Types of lung cancer-directed treatments were recorded, and frequencies of self-reported menopause at each survey were calculated. RESULTS: A cohort of 182 premenopausal women were included in this study, with average age at lung cancer diagnosis 43 years (SD 6). Among the 85 patients who received chemotherapy, 64{\%} self-reported that they had become menopausal within a year of diagnosis. Platinum salts were universally included in these chemotherapy regimens, and the majority of these women also received taxanes within 1 year of diagnosis. Only 15{\%} of the 94 patients who did not receive systemic therapy within 1 year of diagnosis experienced self-reported menopause. Three patients received targeted therapy alone, two of whom remained premenopausal at the final qualifying survey, completed a median of 3 years after diagnosis. CONCLUSIONS: Chemotherapy for lung cancer patients appears to increase risk of early loss of menses in survivors.",
author = "Cathcart-Rake, {Elizabeth J.} and Ruddy, {Kathryn J} and Ruchi Gupta and Kremers, {Walter K} and Kelly Gast and Su, {H. Irene} and Partridge, {Ann H.} and Stewart, {Elizabeth A} and Han Liu and Yanqi He and Ping Yang",
year = "2019",
month = "3",
day = "1",
doi = "10.1097/GME.0000000000001199",
language = "English (US)",
volume = "26",
pages = "306--310",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Amenorrhea after lung cancer treatment

AU - Cathcart-Rake, Elizabeth J.

AU - Ruddy, Kathryn J

AU - Gupta, Ruchi

AU - Kremers, Walter K

AU - Gast, Kelly

AU - Su, H. Irene

AU - Partridge, Ann H.

AU - Stewart, Elizabeth A

AU - Liu, Han

AU - He, Yanqi

AU - Yang, Ping

PY - 2019/3/1

Y1 - 2019/3/1

N2 - OBJECTIVE: More than 5,000 premenopausal women are diagnosed with lung cancer annually in the United States. Limited data exist regarding the risk of treatment-related amenorrhea, a surrogate for infertility and early menopause, after systemic therapies for lung cancer. METHODS: Premenopausal women diagnosed with lung cancer under age 50 were surveyed at diagnosis and annually thereafter about their menstrual status as a part of the Mayo Clinic Epidemiology and Genetics of Lung Cancer Research Program. Types of lung cancer-directed treatments were recorded, and frequencies of self-reported menopause at each survey were calculated. RESULTS: A cohort of 182 premenopausal women were included in this study, with average age at lung cancer diagnosis 43 years (SD 6). Among the 85 patients who received chemotherapy, 64% self-reported that they had become menopausal within a year of diagnosis. Platinum salts were universally included in these chemotherapy regimens, and the majority of these women also received taxanes within 1 year of diagnosis. Only 15% of the 94 patients who did not receive systemic therapy within 1 year of diagnosis experienced self-reported menopause. Three patients received targeted therapy alone, two of whom remained premenopausal at the final qualifying survey, completed a median of 3 years after diagnosis. CONCLUSIONS: Chemotherapy for lung cancer patients appears to increase risk of early loss of menses in survivors.

AB - OBJECTIVE: More than 5,000 premenopausal women are diagnosed with lung cancer annually in the United States. Limited data exist regarding the risk of treatment-related amenorrhea, a surrogate for infertility and early menopause, after systemic therapies for lung cancer. METHODS: Premenopausal women diagnosed with lung cancer under age 50 were surveyed at diagnosis and annually thereafter about their menstrual status as a part of the Mayo Clinic Epidemiology and Genetics of Lung Cancer Research Program. Types of lung cancer-directed treatments were recorded, and frequencies of self-reported menopause at each survey were calculated. RESULTS: A cohort of 182 premenopausal women were included in this study, with average age at lung cancer diagnosis 43 years (SD 6). Among the 85 patients who received chemotherapy, 64% self-reported that they had become menopausal within a year of diagnosis. Platinum salts were universally included in these chemotherapy regimens, and the majority of these women also received taxanes within 1 year of diagnosis. Only 15% of the 94 patients who did not receive systemic therapy within 1 year of diagnosis experienced self-reported menopause. Three patients received targeted therapy alone, two of whom remained premenopausal at the final qualifying survey, completed a median of 3 years after diagnosis. CONCLUSIONS: Chemotherapy for lung cancer patients appears to increase risk of early loss of menses in survivors.

UR - http://www.scopus.com/inward/record.url?scp=85062060336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062060336&partnerID=8YFLogxK

U2 - 10.1097/GME.0000000000001199

DO - 10.1097/GME.0000000000001199

M3 - Article

C2 - 30153217

AN - SCOPUS:85062060336

VL - 26

SP - 306

EP - 310

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 3

ER -